journal article·2019-02-28

Interaction of Human α-1-Acid Glycoprotein (AGP) with Citrate-Stabilized Gold Nanoparticles: Formation of Unexpectedly Strong Binding Events

Fakhrossadat Mohammadi, Amin Sahraei, Chengnan Li, Aurélien Haustrate, V’yacheslav Lehen’kyi, Alexandre Barras, Rabah Boukherroub, Sabine Szunerits

Publisher page

Abstract

Numerous studies have investigated the interaction of high-abundance plasma proteins with different nanostructures. In this work, we focus on the interaction of citrate-stabilized spherical gold nanoparticles (Au-CIT) with human α-1-acid glycoprotein (AGP), one of the major acute phase proteins in humans with a normal plasma concentration between 0.6 and 1.2 mg mL –1, which can increase 4-fold in response to systemic tissue injury, inflammation, or infection. It is shown using different physicochemical approaches that AGP interaction not only takes place readily on Au-CIT nanoparticles, but the binding constant is as high as 10 12 M –1, being several orders of magnitude larger than other highly abundant serum proteins. The adsorbed AGP preserved its biological identity and the formed Au-CIT/AGP particles were nontoxic to cells over a large concentration range. This is in contrast to positively charged gold nanostructures, which displayed lower binding affinity to AGP and higher cytotoxicity even at low particle concentrations. The in vivo investigations showed that the Au-CIT/AGP particles are mostly distributed in the liver and spleen and are absent in kidney and bladder as well as in peripheral organs like brain, confirming their confinement to the blood vessels.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Protein Interaction Studies and Fluorescence Analysis · Blood properties and coagulation · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), 444 Prof. Sobouti Blvd., Gava Zang, Zanjan 45137-66731, Iran

Univ. Lille, CNRS, Centrale Lille, ISEN, Univ. Valenciennes, UMR 8520-IEMN, F-59000 Lille, France

Univ. Lille, Inserm, U1003—PHYCELL—Physiologie Cellulaire, LABEX ICST, F-59000 Lille, France

Funding

Iran National Science Foundation · European Regional Development Fund · Centre National de la Recherche Scientifique · Université Lille 1 - Sciences et Technologies · Région Hauts-de-France

References (55)

Show source-provided references
1. 10.1021/ml300374210.1021/ml3003742 ↗
2. 10.1002/anie.20080258510.1002/anie.200802585 ↗
3. 10.2217/nnm.15.18810.2217/nnm.15.188 ↗
4. 10.1016/j.tibtech.2016.08.01110.1016/j.tibtech.2016.08.011 ↗
5. 10.1038/nnano.2010.18210.1038/nnano.2010.182 ↗
6. 10.1016/j.nantod.2016.10.00510.1016/j.nantod.2016.10.005 ↗
7. 10.1038/ncomms1177010.1038/ncomms11770 ↗
8. 10.1002/smll.20120224310.1002/smll.201202243 ↗
9. 10.1371/journal.pone.008667010.1371/journal.pone.0086670 ↗
10. 10.1021/nn201950e10.1021/nn201950e ↗
11. 10.1016/j.jconrel.2018.01.00210.1016/j.jconrel.2018.01.002 ↗
12. 10.1002/smll.20150160310.1002/smll.201501603 ↗
13. 10.1039/C7NR01523B10.1039/C7NR01523B ↗
14. 10.1021/nl403419e10.1021/nl403419e ↗
15. Vroman L. · Blood · 1980 · 55 · 15610.1182/blood.V55.1.156.156 ↗
16. 10.1016/S0167-4838(00)00153-910.1016/S0167-4838(00)00153-9 ↗
17. 10.1111/j.1365-2125.1991.tb03904.x10.1111/j.1365-2125.1991.tb03904.x ↗
18. 10.1086/31512310.1086/315123 ↗
19. 10.1016/j.nano.2017.01.01910.1016/j.nano.2017.01.019 ↗
20. 10.1039/C4TB01760A10.1039/C4TB01760A ↗
21. 10.1016/j.colsurfb.2006.08.00510.1016/j.colsurfb.2006.08.005 ↗
22. 10.1021/jp057097210.1021/jp0570972 ↗
23. Balaram V. · Atom. Spectrosc. · 2012 · 33 · 4110.46770/AS.2012.02.001 ↗
24. 10.1186/s12951-015-0114-410.1186/s12951-015-0114-4 ↗
25. 10.1021/jp984796o10.1021/jp984796o ↗
26. 10.1021/la504000v10.1021/la504000v ↗
27. 10.1517/17425255.2013.79036410.1517/17425255.2013.790364 ↗
28. 10.1016/j.jcis.2017.07.01110.1016/j.jcis.2017.07.011 ↗
29. 10.1016/j.jmb.2008.09.02010.1016/j.jmb.2008.09.020 ↗
30. 10.1007/s12575-009-9008-x10.1007/s12575-009-9008-x ↗
31. 10.1088/1468-6996/16/3/03461010.1088/1468-6996/16/3/034610 ↗
32. 10.1016/j.dental.2009.06.00810.1016/j.dental.2009.06.008 ↗
33. 10.1021/bi00745a02010.1021/bi00745a020 ↗
34. 10.1021/j100809a02010.1021/j100809a020 ↗
35. 10.1021/nn901118710.1021/nn9011187 ↗
36. 10.1021/la402920f10.1021/la402920f ↗
37. 10.1021/acs.jpcb.5b0043610.1021/acs.jpcb.5b00436 ↗
38. 10.1006/abio.1997.232610.1006/abio.1997.2326 ↗
39. 10.1021/la901735d10.1021/la901735d ↗
40. 10.1021/bi00514a01710.1021/bi00514a017 ↗
41. 10.1016/0006-291X(91)90435-A10.1016/0006-291X(91)90435-A ↗
42. Miller J. N. · Proc. Anal. Div. Chem. Soc. · 1979 · 16 · 203
43. 10.1016/0076-6879(86)30013-210.1016/0076-6879(86)30013-2 ↗
44. 10.1073/pnas.12012039710.1073/pnas.120120397 ↗
45. 10.1021/jp302149710.1021/jp3021497 ↗
46. 10.1021/la903186510.1021/la9031865 ↗
47. 10.1021/cm303708p10.1021/cm303708p ↗
48. 10.1142/s179398441540002410.1142/s1793984415400024 ↗
49. 10.1039/C5RA24662H10.1039/C5RA24662H ↗
50. 10.1016/j.mser.2009.02.00210.1016/j.mser.2009.02.002 ↗
51. 10.1021/jp050728810.1021/jp0507288 ↗
52. 10.1021/nn800466c10.1021/nn800466c ↗
53. Baas J. · Z. Gastroenterol. · 1994 · 32 · 117
54. 10.1002/hep.2203410.1002/hep.22034 ↗
55. 10.1038/nri166910.1038/nri1669 ↗